Pfizer (NYSE:PFE) Stock Rating Lowered by DZ Bank

Pfizer (NYSE:PFE) was downgraded by equities researchers at DZ Bank from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday, Marketbeat reports.

Other equities research analysts have also recently issued reports about the stock. Argus set a $40.00 price target on shares of Pfizer in a research note on Wednesday. Royal Bank Of Canada boosted their price objective on shares of Pfizer from $25.00 to $28.00 and gave the company a “sector perform” rating in a research report on Wednesday. HSBC boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, September 10th. Cantor Fitzgerald upped their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Thursday, October 8th. Finally, UBS Group raised their target price on shares of Pfizer from $27.00 to $30.00 and gave the stock a “neutral” rating in a research report on Wednesday. Five analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $29.94.

Pfizer Stock Down 2.9%

PFE opened at $29.91 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.42 and a debt-to-equity ratio of 0.67. The firm has a market cap of $170.46 billion, a P/E ratio of 42.72, a PEG ratio of 2.04 and a beta of 0.31. Pfizer has a 52 week low of $23.62 and a 52 week high of $31.44. The business’s fifty day simple moving average is $28.72 and its 200 day simple moving average is $26.88.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.13. Pfizer had a return on equity of 19.88% and a net margin of 6.34%. The firm had revenue of $16.58 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same quarter last year, the business posted $0.87 EPS. The firm’s quarterly revenue was down .4% compared to the same quarter last year. As a group, equities research analysts anticipate that Pfizer will post 3.02 EPS for the current fiscal year.

Institutional Investors Weigh In On Pfizer

A number of institutional investors have recently bought and sold shares of PFE. BlackRock Inc. lifted its position in shares of Pfizer by 6.3% during the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after purchasing an additional 31,412,883 shares during the last quarter. State Street Corp boosted its stake in Pfizer by 1.8% during the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock valued at $7,394,749,000 after purchasing an additional 5,501,032 shares during the period. Bank of New York Mellon Corp grew its holdings in Pfizer by 7.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 57,879,546 shares of the biopharmaceutical company’s stock valued at $1,393,739,000 after buying an additional 3,999,646 shares during the last quarter. Bank of America Corp DE acquired a new stake in Pfizer in the 2nd quarter valued at approximately $1,049,602,000. Finally, Dimensional Fund Advisors LP increased its position in Pfizer by 0.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company’s stock worth $1,022,606,000 after buying an additional 293,029 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat quarterly earnings and revenue expectations, and reports say it raised its 2026 outlook. Growth from newer and acquired products helped offset margin pressure, supporting confidence in the company’s turnaround. Pfizer Q3 Earnings Rebuild Confidence As New Drugs Gain Ground
• Positive Sentiment: Citigroup raised its price target on Pfizer, while a UBS analyst said the shares could rise. These calls add to favorable analyst sentiment following the earnings report. Pfizer Stock Gets Price Target Bump from Citigroup Pfizer Stock Price Expected to Rise, UBS Group Analyst Says
• Positive Sentiment: Pfizer is advancing a Phase 3 study of a monthly obesity drug. Progress in this competitive market could provide a future growth opportunity, although clinical results and commercial success remain uncertain. Pfizer Advances Monthly Obesity Drug Study
• Neutral Sentiment: Not all analysts are signaling strong upside: Goldman Sachs maintained a Hold rating, and recent target increases from Citi and UBS were accompanied by Neutral ratings. This suggests analysts see reasons for optimism but are not uniformly convinced of a major near-term rerating. Goldman Sachs Remains a Hold on Pfizer

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.